pharma · Anemia · Anemia Associated With Chronic Kidney Disease · AKBA
Akebia Europe
Akebia Europe Limited
Akebia Europe patent portfolio — 28 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2007
- Employees
- 271
- Programs
- 25
- Drugs
- 13
- Patents
- 28
Akebia Europe patents
28 pharmaceutical patents indexed for Akebia Europe. 0 expire within 24 months.
Akebia Europe has 28 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12419877
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 11883386
Prolyl hydroxylase inhibitors and methods of use
granted -
US 11857543
Compositions and methods for treating anemia
granted -
US 11844756
Compositions and methods for treating anemia
granted -
US 11690836
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 11524939
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
granted -
US 11426393
Prolyl hydroxylase inhibitors and methods of use
granted -
US 11324734
Compositions and methods for treating anemia
granted -
US 11267785
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
granted -
US 11065237
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 10738010
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides
granted -
US 10729681
Prolyl hydroxylase inhibitors and methods of use
granted -
US 10596158
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 10246416
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides
granted -
US 10149842
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 10150734
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
granted -
US 9987262
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 9776969
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
granted -
US 9701636
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
granted -
US 9598370
Prolyl hydroxylase inhibitors and methods of use
granted -
US 9145366
Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides
granted -
US 8940773
Prolyl hydroxylase inhibitors and methods of use
granted -
US 8865748
Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
granted -
US 8722895
Prolyl hydroxylase inhibitors and method of use
granted -
US 8598210
Prolyl hydroxylase inhibitors and methods of use
granted -
US 8343952
Prolyl hydroxylase inhibitors and methods of use
granted -
US 8323671
Prolyl hydroxylase inhibitors and methods of use
granted -
US 8133894
N-benzyl-4-methyleneamino-3-hydroxy-2-pyridones
granted
Frequently asked questions
How many patents does Akebia Europe have?
28 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Akebia Europe patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.